MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Tri-Heal Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Tri-Heal is a research-grade multi-peptide healing blend that combines BPC-157, TB-500 (the N-terminal actin-binding fragment of thymosin beta-4), and a third component (most commonly GHK-Cu or KPV depending on the supplier) into a single reconstitution vial, marketed for soft-tissue and wound-healing research applications. The mechanistic rationale layers complementary repair pathways: BPC-157 upregulates VEGFR2 and the nitric oxide system to drive angiogenesis, TB-500 sequesters monomeric G-actin to enable cell migration and endothelial progenitor recruitment, and GHK-Cu (when included) supports copper-dependent lysyl oxidase activity, collagen and elastin synthesis, and antioxidant defense, while KPV variants add NF-kB-mediated anti-inflammatory and antimicrobial tone. Researchers study blends like Tri-Heal for tendon and ligament injury, post-surgical wound repair, post-burn skin regeneration, and inflammatory tissue models. Source mechanistic literature spans PMID 30915550 (BPC-157) and PMID 17204577 (thymosin beta-4).
Reconstitute: Add 3 mL bacteriostatic water → 15 mg/mL concentration.
Easy measuring: At 15 mg/mL, 1 unit = 0.01 mL = 0.15 mg (150 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Composition variability: Tri-Heal is not a standardized molecule; component ratios and third-peptide identity vary between suppliers. Independent third-party HPLC and mass spectrometry verification is essential before research use.
Onset: Mirrors the slowest component; soft-tissue endpoints in animal models typically respond over 2 to 4 weeks, with anecdotal human reports describing symptom changes over a similar window.
Regulatory status: Not approved by FDA, EMA, or any major regulator. Multiple component peptides (BPC-157, TB-500) are WADA-prohibited. Sold as a research chemical; not intended or labeled for human use.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming or direct stream onto the lyophilized cake.
Gently swirl or roll until fully dissolved (do not shake vigorously).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
Interactive Tri-Heal Syringe Calculator
Currently visualizing the 45 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 45mg dry powder in 3mL water yields 15.00 mg/mL. To evaluate a 250mcg dose, pull to 1.7 units (2 syringe ticks).
U-100 Syringe Representation
1.7 Units (2 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
| Weeks 9–10 | 2500 mcg | 2.5 mg | 16.7 units | 0.167 mL |
| Weeks 11–12 | 3000 mcg | 3.0 mg | 20 units | 0.20 mL |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
| Weeks 9–10 | 2500 mcg | 2.5 mg | 16.7 units | 0.167 mL |
| Weeks 11–12 | 3000 mcg | 3.0 mg | 20 units | 0.20 mL |
| Weeks 13–14 | 3500 mcg | 3.5 mg | 23.3 units | 0.233 mL |
| Weeks 15–16 | 4000 mcg | 4.0 mg | 26.7 units | 0.267 mL |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 45 mg vial.
Peptide Vials (Tri-Heal, 45 mg each):
- check8 weeks (56 doses, ~70 mg total): 2 vials
- check12 weeks (84 doses, ~147 mg total): 4 vials
- check16 weeks (112 doses, ~252 mg total): 6 vials
Insulin Syringes (U-100): Recommendation: Include 30-unit or 50-unit syringes for the early low-dose phases (Weeks 1–4) where precision is critical.
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- check12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- check16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
Tri-Heal layers three mechanistically complementary regenerative peptides in a single vial intended for sequential or combined subcutaneous research administration. The TB-500 component (typically 25 mg per vial) provides the actin-sequestering activity of the thymosin beta-4 active region, promoting cellular migration of fibroblasts, keratinocytes, endothelial cells, and progenitor cells to the site of injury through regulated G-actin to F-actin polymerization dynamics [4][5]. TB-500 also has direct angiogenic effects through endothelial cell motility and anti-inflammatory effects through modulation of cytokine release. The BPC-157 component (typically 10 mg per vial) provides VEGFR2-mediated angiogenesis through activation of the Akt-eNOS axis, ERK1/2-mediated fibroblast and muscle satellite cell proliferation, and approximately 3-fold upregulation of growth hormone receptor expression in tendon fibroblasts that sensitizes them to endogenous growth hormone signaling [6][7][10]. The KPV component (typically 10 mg per vial) provides anti-inflammatory activity through inhibition of NF-kB nuclear translocation in macrophages and intestinal epithelial cells, suppressing transcription of TNF-alpha, IL-1beta, IL-6, IL-8, and IFN-gamma, and modulating leukocyte adhesion and migration into inflamed tissues [8][9][11]. The biological rationale is that effective tissue regeneration requires three coordinated processes: vascular infrastructure to deliver oxygen and nutrients (BPC-157), cellular machinery to migrate to and operate within that vascular framework (TB-500), and control of the inflammatory environment that would otherwise impede those cellular activities (KPV). Pharmacokinetically the three peptides are quite different. BPC-157 is unusually stable in gastric juice and serum but has not been pharmacokinetically characterized in humans; TB-500 has a plasma half-life of approximately 2 hours with substantial tissue retention; KPV has a short plasma half-life of minutes but localized tissue accumulation in inflamed tissues through PepT1-mediated transport. The conventional research route is daily subcutaneous injection in the abdomen or thigh; some protocols inject near the site of injury for BPC-157-equivalent local effect. Common research dosing reconstitutes a vial containing 25 mg TB-500, 10 mg BPC-157, and 10 mg KPV in 3 mL bacteriostatic water, with a daily dose of 0.075 to 0.1 mL delivering approximately 250 mcg BPC-157, 600 to 800 mcg TB-500, and 250 mcg KPV; the TB-500 loading phase may use up to twice this volume two to three times per week with BPC-157 and KPV delivered as separate daily injections for finer control. Cycles typically last 4 to 8 weeks. Common research applications include complex multi-tissue orthopedic injuries, post-surgical recovery, chronic tendinopathy, sports injury rehabilitation, inflammatory bowel disease combined with extraintestinal manifestations, and any context where simultaneous vascular, cellular, and inflammatory modulation is desired.
Clinical Trial Efficacy Highlights
- starNo randomized controlled trial of the Tri-Heal combination has been published; efficacy claims rest entirely on inference from the independent preclinical evidence bases for TB-500, BPC-157, and KPV [1][2][3].
- starTB-500 preclinical evidence includes Goldstein and colleagues' demonstrations of accelerated wound healing, increased angiogenesis, and improved cardiac repair after myocardial infarction in animal models, together with phase 2 ulcer trials showing accelerated healing in approximately 25 percent of treated patients [4][5].
- starBPC-157 preclinical evidence includes Sikiric and colleagues' demonstrations of accelerated tendon healing in transected Achilles models, reduced gastric and intestinal ulcer area in NSAID-induced damage models, and protection across multiple organ systems in toxic and ischemic insults [6][12].
- starChang and colleagues showed in tendon fibroblasts that BPC-157 enhances cell outgrowth, survival, migration, and growth hormone receptor expression by approximately 3-fold, providing the mechanistic basis for the tendon-healing component of the blend [7][10].
- starKPV preclinical evidence includes Dalmasso and Merlin's demonstration in Gastroenterology that PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation in DSS-induced colitis at 205 mcg/day in drinking water, supporting the anti-inflammatory component [9].
- starBrzoska and colleagues reviewed in Endocrine Reviews the broad anti-inflammatory and immunomodulatory activity of alpha-MSH-derived tripeptides including KPV, supporting use in immune-mediated inflammatory disease research [8].
- starThe biological rationale for the combination is strong on first principles, but the absence of head-to-head comparison versus individual peptides or two-peptide combinations means that the incremental benefit of the three-peptide blend over simpler alternatives has not been formally demonstrated.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningBecause Tri-Heal as a compounded blend has not been evaluated in any controlled clinical trial, the side effect profile is inferred from the constituent peptides; each is broadly described as well tolerated in preclinical and limited human pilot studies.
- warningInjection site reactions including erythema, transient pain, and pruritus are common with the daily subcutaneous administration; rotating injection sites between abdomen and thigh helps minimize local discomfort.
- warningTheoretical concerns about angiogenesis-related effects on occult malignancy apply to both TB-500 and BPC-157; the combination doubles this theoretical concern without clinical evidence to confirm or refute it.
- warningBoth TB-500 and BPC-157 are on the WADA Prohibited List under category S2; competitive athletes using Tri-Heal face sanctions if detected, regardless of which component is identified.
- warningKPV-related immunosuppression is a theoretical concern with prolonged high-dose use, although not demonstrated in published studies; combining with other immunomodulators warrants caution.
- warningLong-term safety data are essentially absent; published human exposure to any component is limited to short-term courses, and chronic combination dosing safety is not characterized.
- warningCompounded multi-peptide vials have additional risks of dose variability, contamination, and labeling errors compared with single-peptide preparations; quality control depends entirely on the compounding pharmacy or manufacturer.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Tri-Heal dosage?expand_more
A common protocol reconstitutes a 45 mg vial (25 mg TB-500, 10 mg BPC-157, 10 mg KPV) in 3 mL bacteriostatic water and delivers approximately 0.075 to 0.1 mL subcutaneously daily, providing approximately 250 mcg BPC-157, 600 to 800 mcg TB-500, and 250 mcg KPV per injection. Cycles run 4 to 8 weeks.
How is Tri-Heal used in research protocols?expand_more
Research applications include complex multi-tissue orthopedic injuries, post-surgical recovery, chronic tendinopathy, sports injury rehabilitation, and any context combining vascular, cellular, and inflammatory modulation. Outcome measures parallel those used for the individual peptides.
Can Tri-Heal be combined with other peptides?expand_more
Tri-Heal is sometimes paired with GHK-Cu (copper tripeptide for tissue remodeling) or growth hormone secretagogues such as ipamorelin and CJC-1295 for systemic anabolic support. The combination is mechanistically reasonable but lacks formal pharmacokinetic interaction data.
What are the side effects of Tri-Heal?expand_more
Most users report only mild injection site reactions. Theoretical concerns about angiogenesis effects on occult malignancy apply to both TB-500 and BPC-157. KPV-related immunosuppression with prolonged high-dose use is a theoretical concern. The combination is WADA-banned for competitive athletes.
Is Tri-Heal FDA approved?expand_more
No. Tri-Heal is not FDA approved as a fixed-combination product, nor are any of its individual components (TB-500, BPC-157, KPV) approved for any indication. It is used only in research contexts; compounded multi-peptide products carry additional regulatory and quality control concerns.
Academic References & Study Citations
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. View Scientific Paper →
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. View Scientific Paper →
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. View Scientific Paper →
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. View Scientific Paper →
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. View Scientific Paper →
Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. View Scientific Paper →
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View Scientific Paper →
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. View Scientific Paper →
Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. View Scientific Paper →
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. View Scientific Paper →
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. View Scientific Paper →
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Curr Sports Med Rep. 2025;24(8):278-289. View Scientific Paper →